Literature DB >> 27177492

Severe eosinophilic asthma and mepolizumab.

Garry M Walsh1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27177492     DOI: 10.1016/S2213-2600(16)30103-5

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  1 in total

1.  Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities.

Authors:  Claudia Crimi; Raffaele Campisi; Giulia Cacopardo; Rossella Intravaia; Santi Nolasco; Morena Porto; Corrado Pelaia; Nunzio Crimi
Journal:  World Allergy Organ J       Date:  2020-09-18       Impact factor: 4.084

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.